SCHEMBL22014900

SCHEMBL22014900

Cc1cc(C(F)(F)F)cc(O)c1CC(=O)N=S(N)(=O)c1cccc(CC(C)C)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36
HSD17B2 P37059 1/20 0.34
EPHX1 P07099 3/20 0.33
CA2 P00918 2/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA9 Q16790 1/20 0.33
RORC P51449 1/20 0.33
NPSR1 Q6W5P4 2/20 0.32
F2 P00734 1/20 0.32
PRSS1 P07477 1/20 0.32
PRSS2 P07478 1/20 0.32
PRSS3 P35030 1/20 0.32
IDH1 O75874 2/20 0.32
TRPV1 Q8NER1 1/20 0.32
ELANE P08246 1/20 0.31
P2RX1 P51575 1/20 0.31
SIGMAR1 Q99720 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21962071 0.85 ALDH1A1 (0.40) HSD17B2CA2CA12CA1CA9
SCHEMBL21962052 0.73 BACE1 (0.41) CA2CA12CA1CA9
SCHEMBL22014434 0.66 AGBL2 (0.40) P2RX1
SCHEMBL23568744 0.66 CACNA1B (0.50) HTR2AHTR2CHTR2BEPHX1CA2
SCHEMBL8191003 0.66 CA2 (0.55) CA2CA12CA1CA9
SCHEMBL10182144 0.65 HTR2A (0.41) HTR2AHTR2CHTR2BRORCSIGMAR1
SCHEMBL10180467 0.64 HTR2A (0.41) HTR2AHTR2CHTR2BRORCSIGMAR1
SCHEMBL23447684 0.63 CA12 (0.55) CA2CA12CA1CA9NPSR1
SCHEMBL23665873 0.63 NPC1 (0.42) HTR2AHTR2CHTR2BCA2
SCHEMBL13241241 0.63 ALDH1A1 (0.47) RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020102574-A1 THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS INFLAMMASOME RESEARCH, INC. (US) 2020-05-22 WO disclosed